Thiazole antifungals
Thiazole antifungals are a subset of the azole family, characterized by a thiazole functional group that consists of a five-membered ring containing one nitrogen and one sulfur atom. This group differentiates them from other azoles like imidazoles and triazoles, which contain two and three nitrogen atoms, respectively. Thiazole antifungals function by inhibiting the cytochrome P450 demethylase enzyme, which is vital in converting lanosterol to ergosterol within fungal cell membranes. This inhibition leads to an accumulation of lanosterol, resulting in altered membrane permeability and ultimately cell death.
While no thiazole antifungals are currently approved for human use, research shows potential for several derivatives against fungal infections, including Candida albicans and Cryptococcus neoformans, particularly in individuals with compromised immune systems. Additionally, thiazole derivatives are utilized in agricultural fungicides and antiparasitic agents, such as thiabendazole and mebendazole, although some have been withdrawn from human use in certain regions. Ongoing research in the 2020s suggests that new thiazole compounds may play a crucial role in developing more effective antifungal treatments, especially for resistant infections in vulnerable populations.
Thiazole antifungals
Definition
Thiazole antifungals belong to the azole family, which includes imidazole and triazole. These three can be differentiated from the other members in this family by the presence of a thiazole functional group, a five-membered ring containing one nitrogen and one sulfur. Imidazole groups are similar rings with two nitrogens, whereas triazoles contain three nitrogens.
Mechanism of Action
Thiazole antifungals act in a similar fashion to imidazole and triazole antifungals. All drugs in this family work by inhibiting cytochrome P450 demethylase, an enzyme responsible for converting lanosterol to ergosterol. Blocking this conversion leads to a buildup of lanosterol, which is not typically present in fungal cell walls to the extent it is in ergosterol. Lanosterol contains a 14 alpha-methyl group not present in ergosterol; this chemical substitution results in a different shape and different physical properties of this sterol. The fungal cell membrane thereby exhibits permeability changes and becomes leaky, allowing key cellular components to exit the cell. This leads to cell death.
Drugs in This Class
No drugs containing these groups are approved to treat fungal infections in humans, but several trisubstituted thiazole derivatives are being investigated. Researchers in Saudi Arabia report that four compounds in a series of thiazole derivatives showed significant activity against Candida albicans, and thirteen were somewhat active against gram-positive bacteria, including Staphylococcus aureus and Bacillus subtilis. A research group from Greece also reported significant antifungal and antibacterial activity with a series of thirteen thiadiazole derivatives.
Other researchers have had promising results against Cryptococcus neoformans with a thiazol-4-one derivative. The agent showed fungicidal activity and could be useful in developing new agents against cryptococcosis, a fungal infection that can be life-threatening in persons with impaired immune systems.
None of the foregoing derivatives have undergone clinical testing, but all have shown some promise in developing new antifungal agents.
Thiazole-Based Fungicides and Antiparasitic Agents
Several fungicides containing thiazole groups are commonly used worldwide in the agricultural industry to improve yield and plant quality. Thiabendazole is one common agent used to control mold, blight, and other fungal diseases in fruits and vegetables and parasitic infections in livestock. It had been available as an oral suspension or tablet for human use against parasites. However, by order of the US Food and Drug Administration, distribution has been discontinued in the United States. A topical product is available in other countries. Mebendazole (Vermox) is available as a tablet for treating parasitic infections such as ringworm and hookworm.
Impact
Immunocompromised persons are susceptible to several fungal infections that healthy persons can easily fight. The infections include C. albicans and C. neoformans, which often become resistant to broad-spectrum antifungal agents. Newer agents must constantly be developed, particularly for those persons with impaired immune systems because of human immunodeficiency virus (HIV) infection, chemotherapy, or organ transplantation. In the 2020s, scientists announced the synthesis of new thiazole derivatives that showed promising antifungal activity against C. albicans isolates.
Bibliography
Al-Saadi, M. S., H. M. Faidallah, and S. A. Rostom. "Synthesis and Biological Evaluation of Some 2,4,5-Trisubstituted Thiazole Derivatives as Potential Antimicrobial and Anticancer Agents." Archiv der Pharmazie—Chemistry in Life Sciences, vol. 341, 2008, pp. 424-434.
Biernasiuk, Anna, et al. "The Newly Synthesized Thiazole Derivatives As Potential Antifungal Compounds against Candida Albicans." Applied Microbiology and Biotechnology, vol. 105, no. 16-17, 2021, p. 6355, doi.org/10.1007/s00253-021-11477-7. Accessed 9 Nov. 2024.
Camoutsis, C., et al. "Sulfonamide-1,2,4-Thiadiazole Derivatives as Antifungal and Antibacterial Agents: Synthesis, Biological Evaluation, Lipophilicity, and Conformational Studies." Chemical and Pharmaceutical Bulletin, vol. 58, 2010, pp. 160-167.
Griffith, R. K. "Antifungal Drugs." Foye’s Principles of Medicinal Chemistry, edited by Thomas L. Lemke and William O. Foye. 6th ed., Wolters Kluwer, 2008.
Gullo, Antonio. "Invasive Fungal Infections." Drugs, vol. 69, 2009, pp. 65-73.
Insuasty, B., et al. "Fungicide Activity of 5-(4-Chlorobenzylidene)-(Z)-2-Dimethylamino-1,3-Thiazol-4-One Against Cryptococcus neoformans." Archiv der Pharmazie—Chemistry in Life Sciences, vol. 343, 2010, pp. 48-53.
Murray, Patrick R., Ken S. Rosenthal, and Michael A. Pfaller. Medical Microbiology. 6th ed., Mosby/Elsevier, 2009.
Ryan, Kenneth J. "Pathogenesis of Fungal Infection." Sherris Medical Microbiology, edited by Kenneth J. Ryan and C. George Ray. 5th ed., McGraw-Hill, 2010.
Sayed, Mariam T., and Salwa A. Elsharabasy. "Synthesis and Antimicrobial Activity of New Series of Thiazoles, Pyridines and Pyrazoles Based on Coumarin Moiety." Scientific Reports, vol. 13, no. 1, 2023, pp. 1-9, doi.org/10.1038/s41598-023-36705-0. Accessed 9 Nov. 2024.
Teixeira, Melissa M., et al. "New Antifungal Agents with Azole Moieties." Pharmaceuticals, vol. 15, no. 11, 2022, p. 1427, doi.org/10.3390/ph15111427. Accessed 9 Nov. 2024.